Wyeth Pharmaceuticals, Progenics drug has study setback
pharmiweb.co.uk     May 23, 2008            

Wyeth Pharmaceuticals and Progenics Pharmaceuticals said Thursday their experimental drug Relistor, in intravenous form, did not meet primary or secondary end points related to treating bowel dysfunction caused by the use of opioid pain relief medication after abdominal surgery. The companies are... [read full story]                    


View all news articles about*:
Adolor GlaxoSmithKline Pharmaceuticals Progenics Research Wyeth
*Newstin tag cloud displays all featured persons, associated organizations, related topics, regions and companies

View other selected articles:

                   

Chemical Society To Honor 'Heroes Of Chemistry' During National Meeting

medicalnewstoday.com     Aug 16, 2008   1 related          

Bruce Roth's name may not be on the tip of many tongues, but his invention has been on more than 26 million in the United States alone. Inventor of Lipitor, the cholesterol-lowering pill that is the world's largest selling...                    

comments

The Latest Trends and Research for Drug Discovery in Alzheimer's Disease

redorbit.com     Aug 12, 2008   2 related          

Posted on: Tuesday, 12 August 2008, 15:01 CDT The Alzheimer's Drug Discovery Foundation (ADDF) announces the 9th International Conference on Alzheimer's Disease Drug Discovery, October 6-7, 2008 at The Westin New York at Times...                    

comments

                   

Fort Dodge Animal Health Announces Leptoinfo.com Now Available to Dog Owners (PR Newswire)

yahoo.com     Aug 11, 2008   4 related          

Fort Dodge Animal Health, a division of Wyeth , today announced it has added a dog owners' section on www.leptoinfo.com, a Web site dedicated to providing information and resources to veterinarians and pet owners about...                    

comments

                   

Progenics Pharmaceuticals Reports Second Quarter 2008 Results

redorbit.com     Aug 8, 2008   1 related          

Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced its results of operations for the second quarter and first half of 2008. Revenues for the second quarter ended June 30, 2008 totaled $28.6 million compared to $25.5...                    

comments